Although the United States and Canada reached an agreement to scrap Ottawa’s controversial Digital Services Tax – estimated to cost U.S. companies $1 billion annually – a much larger and ongoing dispute over drug prices is getting less attention.
Canada’s government is keeping the price of American-made pharmaceuticals artificially low while U.S. consumers and taxpayers foot the bill, critics say. Now, some are calling on the U.S. Trade Representative (USTR) to take action.
“Canada funds its welfare state by freeloading on U.S. medical goods and NATO,” Mark Merritt, founder of FAIR Rx, a group opposed to unfair health care trade practices, said in a statement. “Clearly, the savings aren’t passed on to Canadian patients, who have far less access to prescription drugs than Americans.”
Drugs and medical devices are the largest non-commodity U.S. export to Canada, totaling over $14 billion annually, according to Pangea Network.
However, through its Patented Medicine Prices Review Board (PMPRB), Canada caps patented drug prices at 30% to 80% below U.S. levels, a practice flagged as a serious market access concern in the USTR’s 2025 Special 301 Report.
Even so, the USTR has yet to take formal action to challenge Canada’s pricing system as a non-tariff trade barrier. That’s the case even after President Donald Trump issued a May 2025 executive order directing the agency to counter foreign price suppression that unfairly shifts drug research and development costs onto Americans.
Click this link for the original source of this article.
Author: Faith Novak
This content is courtesy of, and owned and copyrighted by, https://www.offthepress.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
